-
Gene-editing therapy for LGMD shows promise in mouse model
A gene-editing therapy designed to correct a defect in the DYSF gene — one that’s […]
-
PPMD’s Race to End Duchenne Program Celebrates 20 Years of Going the Distance to End Duchenne
PPMD is celebrating the 20th anniversary of our endurance fundraising program, Race to End Duchenne, […]
-
How ‘The Remarkable Life of Ibelin’ moved me as a DMD survivor
A few days ago, I watched the Netflix documentary “The Remarkable Life of Ibelin.” I […]
-
Application finalized for DMD cell therapy CAP-1002, now deramiocel
Capricor Therapeutics has completed its submission of a biologics license application (BLA) seeking U.S. approval […]
-
Thank You for Joining us to Advance the Research Evolution
As we enter PPMD’s fourth decade and a new era in Duchenne research, I am […]
-
Capricor completes BLA submission to the FDA for the approval of its investigational cell therapy for Duchenne cardiomyopathy
Capricor Therapeutics, which received early funding from CureDuchenne, has completed a Biologics License Application (BLA) […]
-
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel
PPMD is excited to learn that Capricor Therapeutics has completed the submission of its rolling […]
-
My husband and I make a great team as we care for our sons
Occasionally I struggle to find a topic to write about in my weekly column. I […]
-
Top 10 MD news stories of 2024
During 2024, Muscular Dystrohy News Today covered the latest scientific studies, advances in treatment, and […]
-
New study uncovers key insights into protein interactions in Duchenne muscular dystrophy, paving way for more targeted therapies
A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical […]
